Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIIB, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Clinical Efficacy Study of Baloxavir Marboxil for the Reduction of Direct Transmission of Influenza From Otherwise Healthy Patients to Household Contacts

Next Previous
Trial Profile

A Phase IIIB, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Clinical Efficacy Study of Baloxavir Marboxil for the Reduction of Direct Transmission of Influenza From Otherwise Healthy Patients to Household Contacts

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Baloxavir-marboxil (Primary)
  • Indications Influenza A virus infections; Influenza B virus infections
  • Focus Registrational; Therapeutic Use
  • Acronyms Centerstone
  • Sponsors Roche

Most Recent Events

  • 24 Apr 2025 According to a Genentech media release, the results from this study have been submitted to the USFDA and EMA.
  • 24 Apr 2025 According to a Genentech media release, the New England Journal of Medicine (NEJM) has published a detailed analysis of this study.
  • 19 Sep 2024 Primary endpoint has been met. (Virological Transmission by Day 5), according to a Genentech media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top